# **Special Issue**

# Oromucosal Dosage Forms: Novel Formulation Strategies, Delivery and Release

# Message from the Guest Editors

In the last few decades, the oral cavity has attracted the interest of the scientific community as a promising alternative route for drug administration Both the buccal and sublingual mucosae are highly vascularized, presenting several advantages such as the opportunity to bypass the gastrointestinal tract and first-pass metabolism in the liver. When the sublingual mucosa is chosen as an administration site, the rapid onset of action results in the delivery route being more comfortable and convenient than the intravenous route. Moreover, mouth pathologies ranging from periodontitis to mucositis up to cancerous lesions can greatly benefit from targeted locoregional drug delivery in a manner whereby systemic side effects are avoided. Therefore, the design and characterization of pharmaceutical dosage forms suitable for oral cavity application are of crucial importance. This Special Issue welcomes original research articles and reviews that cover all the aspects of the design, manufacturing, characterization and final formulation of oromucosal drug delivery systems.

#### **Guest Editors**

Dr. Viviana De Caro

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, 90123 Palermo, Italy Dr. Giulia Di Prima

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, 90123 Palermo, Italy

# Deadline for manuscript submissions

closed (31 March 2023)



# **Pharmaceutics**

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/127154

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

#### Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

### **Author Benefits**

# **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

# **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

